Evidence map›Paper›PMID 40072281›Full record

ArticleMolecular oncology2025

Germline variants in CDKN2A wild-type melanoma prone families.

Gjertrud T Iversen, Marie Loeng, Amalie Lund Holth, Per E Lønning, Jürgen Geisler, Stian Knappskog

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gjertrud T IversenDepartment of Clinical Science, K.G. Jebsen Center for Genome-Directed Cancer Therapy, University of Bergen, Bergen, Norway.
Marie LoengDepartment of Oncology, Akershus University Hospital, Lørenskog, Norway.
Amalie Lund HolthDepartment of Oncology, Akershus University Hospital, Lørenskog, Norway.
Per E LønningDepartment of Clinical Science, K.G. Jebsen Center for Genome-Directed Cancer Therapy, University of Bergen, Bergen, Norway.
Jürgen GeislerDepartment of Oncology, Akershus University Hospital, Lørenskog, Norway.ORCID 0000-0001-6239-3856
Stian KnappskogDepartment of Clinical Science, K.G. Jebsen Center for Genome-Directed Cancer Therapy, University of Bergen, Bergen, Norway.ORCID 0000-0002-4153-1655

Funding

Bodil and Magnes Cancer Research Foundation, OsloKreftforeningen
6 · The paper itself

Abstract

Germline pathogenic variants in CDKN2A are well established as an underlying cause of familial malignant melanoma. While pathogenic variants in other genes have also been linked to melanoma, most familial cases remain unexplained. We assessed pathogenic germline variants in 360 cancer-related genes in 56 Norwegian melanoma-prone families. The index cases were selected based on familial history of melanoma and/or multiple primary melanomas, along with previous negative tests for pathogenic CDKN2A variants. We found 6 out of 56 index individuals to carry germline pathogenic or likely pathogenic variants in BRCA2, MRE11, ATM, MSH2, CHEK2, and AR. One family member with melanoma (not index case) carried a pathogenic variant in MAP3K6. In addition, we found a high fraction of variants previously considered benign and/or as variants of uncertain significance in xeroderma pigmentosum-related genes. In particular, XPC

Indexed as

Cyclin-Dependent Kinase Inhibitor p16Genetic Predisposition to DiseaseGerm-Line MutationMelanomaSkin NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPedigreeCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16cancer riskgermline variantsinheritancemelanoma

Identifiers

PMID40072281
PMCPMC12077288

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.